# A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

> **NCT05753722** · PHASE1 · RECRUITING · sponsor: **Incendia Therapeutics** · enrollment: 270 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Non Small Cell Lung Cancer
- NSCLC

## Interventions

- **BIOLOGICAL:** PRTH-101
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05753722
- **Lead sponsor:** Incendia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-03
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753722, "A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05753722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*